Jérôme S.
- Country
- Germany
- Department
- n.a.
Research Overview
- A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Phase II Study of Total Neoadjuvant Durvalumab Plus FLOT Combination Therapy Followed by Postoperative Durvalumab in Resectable Gastroesophageal Adenocarcinoma
- Phase III Randomized Trial of Decitabine, Venetoclax, and Tretinoin in Acute Myeloid Leukemia Patients Ineligible for Induction Chemotherapy
Data & Insights
Has run more than one trial at 104 of 297 partner sites.
Specializations
Gastrointestinal Oncology
This investigator specializes in the treatment of advanced colon cancer, with particular emphasis on developing innovative therapeutic approaches for patients with locally advanced disease.
- Surgical Oncology
- Preoperative Treatment Strategies
- Systemic Therapy Development
The investigator focuses on optimizing treatment sequences for patients with T3-4 stage colon cancer and those with nodal involvement.
Clinical Treatment Optimization
The research interests center on comparing and evaluating different therapeutic approaches in resectable colon cancer, particularly examining the timing and sequencing of treatments.
- Treatment Sequencing
- Multimodal Therapy
- Stage-guided Treatment
Special attention is given to investigating the role of preoperative chemotherapy in improving patient outcomes.
Diagnostic Imaging
The investigator utilizes advanced imaging techniques for precise staging and treatment planning in gastrointestinal oncology.
- CT Imaging Assessment
- MRI Evaluation
- Cancer Staging Protocols
Expertise includes the application of diagnostic imaging for accurate disease assessment and treatment response monitoring.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.